ArticleClinical ophthalmology (Auckland, N.Z.)2025
Efficacy of Topical Non-Selective and COX-2 Selective NSAIDs in Accelerating Resolution of Acute Central Serous Chorioretinopathy: A Retrospective Analysis.
Article in Clinical ophthalmology (Auckland, N.Z.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To evaluate whether topical nonsteroidal anti-inflammatory drugs (NSAIDs) accelerate the resolution of acute central serous chorioretinopathy (CSCR) compared with observation. Patients and methods: This retrospective cohort study reviewed patients diagnosed with acute CSCR (2018-2023) (n = 145). Patients received either topical ketorolac (n = 26, nonselective NSAID, four times daily) or observation alone (n = 63). Historical data (2007-2013) (n = 111) comparing COX-2 selective NSAIDs (bromfenac or nepafenac, n = 38) with observation (n = 73) were analyzed for comparison. Main outcome was time to complete subretinal fluid resolution on optical coherence tomography (OCT) and visual acuity (VA) recovery to 20/20. Outcomes were analyzed using Kaplan-Meier survival curves and Cox proportional-hazards regression. Results: Baseline demographics were similar between NSAID-treated and observed groups (mean age 45 years, ~82% male, baseline visual acuity ~20/40). In the recent cohort, NSAID treatment with ketorolac significantly accelerated fluid resolution compared with observation (median 74 vs 115 days; hazard ratio 1.70, 95% CI 1.05-2.75, p = 0.033). Historical data revealed a greater treatment effect with COX-2 selective NSAIDs (mean resolution 42 days vs 131 days with observation, p < 0.0001). When combined, NSAIDs significantly shortened CSCR duration compared to observation alone (mean 62 vs 132 days, p < 0.001), with COX-2 selective NSAIDs showing superior efficacy (p < 0.01 vs ketorolac). Visual acuity outcomes at final resolution were excellent (~20/20) and similar between groups. No significant adverse events occurred, and 12-month recurrence rates were similar between NSAID-treated and observed groups. Conclusion: Topical NSAIDs, especially COX-2 selective agents, may accelerate resolution of acute CSCR compared to observation alone. The earlier recovery of normal vision and anatomical resolution may benefit patients clinically by reducing morbidity associated with prolonged retinal detachment. Prospective studies are warranted to confirm these findings and refine treatment protocols for acute CSCR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.